CSI Market
Sign In | Register

Crispr Therapeutics Ag (CRSP) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access CRSP Annual Cash Flow →
Cash flow patterns shown here provide context for understanding Crispr Therapeutics Ag's ability to sustain operations and capital deployment.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-214.09
Depreciation & amortization8.60
Amortization of Other Assets0.85
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation33.64
Income (Loss) from Equity Method Investments0.00
Foreign Currency Transaction Gain (Loss), Unrealized0.00
Income Loss From Equity Method Investments And Investment Compensation Expense-
Increase Decrease In Contract With Customer Liability-0.43
Non Cash Expense Related To Collaboration Agreement-
Acquired In Process Research And Development-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable and Accrued Liabilities-18.32
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets1.09
Other Working Capital3.95
Other Noncash Income (Expense)4.76
Other net0.00
Payments for (Proceeds from) Other Operating Activities-12.88
Discontinued operations0.00
Net Cash flow from Operating Activities-192.40
Investing Activities
Capital Expenditures-1.15
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities184.25
Payments to Acquire Marketable Securities-952.39
Real Estate Investments0.00
Proceeds From Contribution Of Intellectual Property To Equity Method Investee-
Net Cash And Restricted Cash Received In Connection With Acquisition Of Controlling Interest-
Payments To Acquire Equity Securities Fv Ni-4.62
Proceeds From Sales Of Marketable Securities147.71
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire in Process Research and Development-2.47
Payments to Acquire Equity Method Investments0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net305.36
Discontinued operations0.00
Net Cash Flow from Investing Activities-466.40
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-14.65
Long-term debt - borrowings600.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock13.74
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Issuance Of Restricted Shares-
Capital Expenditures Incurred But Not Yet Paid-
Debt Conversion Converted Instrument Amount-
Noncash Contribution Of Intellectual Property To Equity Method Investee-
Issuance Costs For Initial Public Offering In Accounts Payable And Accrued Expenses-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities599.09
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-193.55
Total Cash Flow-59.74
4 historic quarters locked

Sign in to unlock the full Crispr Therapeutics Ag cash flow history.

Sign In Create Free Account

About Crispr Therapeutics Ag Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-330672

Figures are derived from filed reports and may be restated. Historical data is subject to revision.